the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

Conditions: Heart Failure

Sex: All

Ages: 1 Month – 18 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 60

Sponsor: Ain Shams University

Location: Ain Shams Hospital Cairo Cairo Governorate

Summary

the study to investigate the efficacy of empagiflozin in pediatric heart failure

Eligibility Criteria

Inclusion Criteria: * • Pediatrics (aged 1months-18 years) * Confirmed HF diagnosis: HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure \> 18 mmHg measured directly and/or the ratio of early diastolic mitral inflow velocity(E) to early diastolic mitral annular velocity (e')( E/e'\>14 by echocardiography) with clinical features of congestion and/or low cardiac output. • Class III or IV of ROSS classification or BNP level more than 300 pg/mL Exclusion Criteria: * • Pediatric with chronic kidney failure * Avoid initiating empagliflozin in patients with concurrent urinary tract infection (UTI). * patients with eGFR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07692256). StuddyBuddy aggregates publicly available trial information.